We report that a high extent of ADAM17 downregulation (∆pADAM17high) during platelet activation in patients—which may occur, among others, after their interaction with metastasizing tumor cells—correlates with certain tumor stages and the occurrence of metastases in breast cancer patients. Here, ADAM17 is linked to breast carcinoma.